But data are early, and other groups are also developing less frequent injections for wet AMD.
A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?